Needham & Company LLC Reaffirms “Buy” Rating for Bicycle Therapeutics (NASDAQ:BCYC)
Needham & Company LLC reaffirmed their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a research note released on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $43.00 price target on the stock. Other equities research analysts have also recently issued research reports about the stock. HC Wainwright […]
More Stories
DOJ Inquiry Into Fed Chair: What to Know
By Andrew Moran The Federal Reserve was thrust into the spotlight on Jan. 11, after chair Jerome Powell said the...
Their Bodies Were Irreversibly Damaged, Now These Former Transgender Teens Are Fighting for Justice
By Darlene McCormick Sanchez Young people who used to identify as transgender have filed dozens of lawsuits in the past...
Hegseth Says Proposed $1.5 Trillion Military Budget Is ‘Message to the World’
By Ryan Morgan War Secretary Pete Hegseth on Jan. 12 said President Donald Trump’s call for a $1.5 trillion military...
Treasury Secretary Says US Can Easily Cover Any Tariff Refunds
By Jack Phillips Treasury Secretary Scott Bessent said that his department can easily cover any refunds related to tariffs if...
Conrad Black: How US Action Against the Iranian Regime Could Play Out
By Conrad Black The world is waiting for President Trump to bring the horrible and sanguinary disaster of the last...
Judge Blocks Parts of Trump’s Election Order on Citizenship Proof, Ballot Deadline Rules
By Tom Ozimek A federal judge has blocked key parts of President Donald Trump’s election-related executive order in Washington state...